Metformin use in Type 2 Diabetes shows inconsistent clinical effects in review

Photo by diabetesmagazijn.nl / Unsplash

Frontiers in Medicine Published April 24, 2026 Medically reviewed April 24, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that metformin effects in Type 2 Diabetes show mechanistic ambiguity and inconsistent clinical findings.

This current review evaluates metformin as an intervention for Type 2 Diabetes management. The population encompasses over 150 million individuals worldwide receiving treatment annually. Sample size and setting were not reported within the review data provided.

Metformin was the sole intervention, with no comparator reported. Primary outcomes were not reported. Secondary outcomes assessed neurocognitive function, gastrointestinal physiology, reproductive endocrinology, cellular aging pathways, glycemic control, metabolic improvement, long-term safety, and pharmacokinetics. Main results were not reported.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Limitations include mechanistically ambiguous effects, clinically inconsistent findings across populations, and incompletely characterized effects. Knowledge gaps impede safe, personalized application of the medication. The certainty note emphasizes distinguishing robustly replicated findings from preliminary or contradictory observations. Do not overstate preliminary or contradictory observations, mechanistically ambiguous, clinically inconsistent across populations, or incompletely characterized data.

Practice relevance requires prospective studies integrating multi-omics profiling and extended follow-up. Clinicians must distinguish robustly replicated findings from preliminary or contradictory observations. Evidence strength is limited by the review nature and lack of specific numerical data available for clinicians.

Follow-up duration is noted as extended follow-up with prospective studies needed. Funding or conflicts were not reported in the input.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedApr 2026

View Original Abstract ↓

Metformin is the first-line oral antihyperglycemic agent for type 2 diabetes mellitus (T2DM), with over 150 million individuals worldwide receiving treatment annually. Although synthesized in 1922, its clinical adoption began in the 1950s, and decades of widespread use have firmly established its efficacy in glycemic control and metabolic improvement. Nevertheless, growing evidence indicates that metformin exerts pleiotropic effects beyond glucose homeostasis—modulating neurocognitive function, gastrointestinal physiology, reproductive endocrinology, and cellular aging pathways. Many of these effects remain incompletely characterized, mechanistically ambiguous, or clinically inconsistent across populations. This review systematically synthesizes recent (2014–2024) preclinical and clinical evidence from PubMed and Google Scholar to critically evaluate the contested physiological and pathophysiological actions of metformin. We distinguish robustly replicated findings from preliminary or contradictory observations, clarify dose- and context-dependent mechanisms (e.g., mitochondrial vs. lysosomal AMPK activation), and highlight knowledge gaps impeding safe, personalized application. Emphasis is placed on reconciling mechanistic insights with real-world therapeutic outcomes—particularly regarding long-term safety, interindividual variability in pharmacokinetics (e.g., OCT/MATE transporter polymorphisms), and the need for prospective studies integrating multi-omics profiling and extended follow-up.